Search research articles
Contact Us
Filters
Showing results (231-240 of 304) with videos related to
Page
of 31
Sort By:
Atherosclerosis
|
February 5, 2026
Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype
G B John Mancini, Arnold Ryomoto, Isabelle Ruel, et al.
Nature Medicine
|
April 7, 2026
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial
Gerald F Watts, Russell Scott, David Sullivan, et al.
Journal of Clinical Lipidology
|
May 12, 2018
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Robert A Hegele, Amanda J Berberich, Matthew R Ban, et al.
Journal of Clinical Lipidology
|
July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
Ewa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.
The Canadian Journal of Cardiology
|
December 3, 2014
Canadian Cardiovascular Society position statement on familial hypercholesterolemia
, Jacques Genest, Robert A Hegele, et al.
Atherosclerosis
|
October 2, 2018
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry
Liam R Brunham, Isabelle Ruel, Etienne Khoury, et al.
The Lancet. Diabetes & Endocrinology
|
April 2, 2021
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Ioanna Gouni-Berthold, Veronica J Alexander, Qingqing Yang, et al.
American Journal of Preventive Cardiology
|
June 15, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials
Christie M Ballantyne, Alexis Baass, Robert S Rosenson, et al.
European Journal of Preventive Cardiology
|
October 19, 2023
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
Raul D Santos, Andrea Ruzza, Bei Wang, et al.
American Heart Journal
|
May 13, 2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study
G Kees Hovingh, Loek P Smits, Claudia Stefanutti, et al.
Page
of 31
Search research articles
Search
Showing results (231-240 of 304) with videos related to
Sort By:
Page
of 31
Atherosclerosis
|
February 5, 2026
Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype
G B John Mancini, Arnold Ryomoto, Isabelle Ruel, et al.
Nature Medicine
|
April 7, 2026
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial
Gerald F Watts, Russell Scott, David Sullivan, et al.
Journal of Clinical Lipidology
|
May 12, 2018
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Robert A Hegele, Amanda J Berberich, Matthew R Ban, et al.
Journal of Clinical Lipidology
|
July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
Ewa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.
The Canadian Journal of Cardiology
|
December 3, 2014
Canadian Cardiovascular Society position statement on familial hypercholesterolemia
, Jacques Genest, Robert A Hegele, et al.
Atherosclerosis
|
October 2, 2018
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry
Liam R Brunham, Isabelle Ruel, Etienne Khoury, et al.
The Lancet. Diabetes & Endocrinology
|
April 2, 2021
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Ioanna Gouni-Berthold, Veronica J Alexander, Qingqing Yang, et al.
American Journal of Preventive Cardiology
|
June 15, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials
Christie M Ballantyne, Alexis Baass, Robert S Rosenson, et al.
European Journal of Preventive Cardiology
|
October 19, 2023
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment
Raul D Santos, Andrea Ruzza, Bei Wang, et al.
American Heart Journal
|
May 13, 2015
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study
G Kees Hovingh, Loek P Smits, Claudia Stefanutti, et al.
Page
of 31